戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 determinant for hypertension and response to antihypertensive therapy.
2 %-0.6%) also met the guideline threshold for antihypertensive therapy.
3  risk, contributing to low use of statin and antihypertensive therapy.
4 ts are often managed with intensification of antihypertensive therapy.
5 ssociated with nonadherence to statin and/or antihypertensive therapy.
6 le to where hypertension is not treated with antihypertensive therapy.
7 lion (95% CI, 2.02 million-3.21 million) for antihypertensive therapy.
8 ween perceived discrimination and suboptimal antihypertensive therapy.
9 se these drugs in patients already receiving antihypertensive therapy.
10 atient was discharged with anticoagulant and antihypertensive therapy.
11 equired further intensification of discharge antihypertensive therapy.
12  RDN emerged as an innovative interventional antihypertensive therapy.
13 or antagonist, or AngII infusion with triple-antihypertensive therapy.
14 ther help advance personalized approaches to antihypertensive therapy.
15 mm Hg diastolic and treated with intravenous antihypertensive therapy.
16 bo required the initiation of or a change in antihypertensive therapy.
17 t is resistant to most forms of conventional antihypertensive therapy.
18 t the study, most were on antithrombotic and antihypertensive therapy.
19  number needed to treat for both statins and antihypertensive therapy.
20  the score components of diabetes and use of antihypertensive therapy.
21 ossibility of targeting the EP1 receptor for antihypertensive therapy.
22 e provider in improving patient adherence to antihypertensive therapy.
23 ians than in African Americans regardless of antihypertensive therapy.
24 he physiologic evidence of renoprotection by antihypertensive therapy.
25 cal cardiovascular disease and not receiving antihypertensive therapy.
26 pine, or placebo in addition to conventional antihypertensive therapy.
27 sease and should be preferred for first-line antihypertensive therapy.
28 kers, should no longer be used as first-line antihypertensive therapy.
29 on who were under evaluation for a change in antihypertensive therapy.
30 disease and those receiving anticoagulant or antihypertensive therapy.
31 those adherent to statin, but nonadherent to antihypertensive, therapy.
32 potential for designing and evaluating novel antihypertensive therapies.
33 versus <=145 mm Hg (standard treatment) with antihypertensive therapies.
34 rovide a potential target for individualized antihypertensive therapies.
35 wer risk of combined MI or stroke than other antihypertensive therapies.
36 59) for those nonadherent both to statin and antihypertensive therapy, 1.82 (95% CI: 1.43 to 2.33) fo
37 nsmitted BP data to pharmacists who adjusted antihypertensive therapy accordingly.
38 olds could reduce eligibility for statin and antihypertensive therapy among 15.8 million US adults.
39 tions between 1953 and 1957 and were free of antihypertensive therapy and cardiovascular disease.
40 ovide validation for TMEM16A as a target for antihypertensive therapy and demonstrate the efficacy of
41         More experience is being gained with antihypertensive therapy and expectant management in sev
42 ians at all exercise workloads regardless of antihypertensive therapy and had over a 90% higher likel
43 kers, represents the backbone of recommended antihypertensive therapy and intense debate about their
44 and of all-cause mortality in the setting of antihypertensive therapy and regression of ECG left vent
45 ith statins and other lipid-lowering agents, antihypertensive therapies, and antihyperglycemic treatm
46 those non-adherent to statin but adherent to antihypertensive therapy, and 1.30 (95% CI: 0.53 to 3.20
47 ead time, reduced effectiveness of intensive antihypertensive therapy, and increased relative risk re
48                   Aspirin, lipid-lowering or antihypertensive therapy, and interim revascularization
49 sk categorization, eligibility for statin or antihypertensive therapy, and projected occurrences of m
50 ramework for addressing patient adherence to antihypertensive therapy, and to propose future directio
51 ludes diuretics as part of the first step of antihypertensive therapy, and updated analysis does not
52 f lifetime discrimination on the underuse of antihypertensive therapy appears partially mediated by d
53 ust, 2010, for randomised clinical trials of antihypertensive therapy (ARBs, angiotensin-converting-e
54     Recent developments concerning pediatric antihypertensive therapy are considered, as well as new
55  various guidelines, but the indications for antihypertensive therapy are relatively similar.
56 d ACEI/ARB and 24,001 (61.1%) received other antihypertensive therapy at year 1 after transplantation
57 multivariable models adjusting for age, sex, antihypertensive therapy, body mass index, heart rate, t
58 nzyme (ACE) inhibitors are used primarily in antihypertensive therapy but also are known to improve w
59 ing fixed-combination, low-dose, triple-pill antihypertensive therapy (consisting of amlodipine, telm
60                  The probability of stopping antihypertensive therapy decreased as compared with the
61 terol, estimated glomerular filtration rate, antihypertensive therapy, diabetes mellitus, and smoking
62 sence of renal failure, and documentation of antihypertensive therapy, diabetic status, proteinuria s
63 further reducing the diastolic pressure with antihypertensive therapy, especially in patients with co
64                                              Antihypertensive therapy, especially with inhibitors of
65 lyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding diuretics) was admin
66     No objective analysis of advertising for antihypertensive therapies exists, however.
67    Large-scale trials to assess the value of antihypertensive therapy for older patients with SBP of
68 te, free of coronary heart disease (CHD) and antihypertensive therapy, from the Chicago Heart Associa
69         The hemodynamics of hypertension and antihypertensive therapy have generally been approached
70 hough black patients received more intensive antihypertensive therapy, Hispanics were undertreated.
71  the pathophysiology, risks, and benefits of antihypertensive therapies in the patient with intracran
72 is the optimal target for BP lowering during antihypertensive therapy in adults?
73 aptured year-by-year adherence to statin and antihypertensive therapy in both study groups and estima
74 e endothelial, cardiac, and renal effects of antihypertensive therapy in hypertension and may explain
75  hypotension; the effectiveness of nocturnal antihypertensive therapy in patients with coexistent neu
76 fined a new risk threshold for initiation of antihypertensive therapy in patients with stage 1 hypert
77 cal trials from 1965 through October 2010 of antihypertensive therapy in patients with type 2 diabete
78 ding the biological mechanisms and choice of antihypertensive therapy in pregnancy should be carefull
79 on, it is important to highlight the role of antihypertensive therapy in primary prevention.
80 t failure (CHF) in the setting of aggressive antihypertensive therapy in unclear.
81                                              Antihypertensive therapy included angiotensin-converting
82 aracteristics associated with an increase in antihypertensive therapy included increased levels of bo
83 nell product electrocardiographic LVH during antihypertensive therapy is associated with a lower like
84 nell product electrocardiographic LVH during antihypertensive therapy is associated with fewer hospit
85 uct and Sokolow-Lyon voltage criteria during antihypertensive therapy is associated with lower likeli
86 ant clinical implications since titration of antihypertensive therapy is currently based on SBP.
87                                      Because antihypertensive therapy is effective in elderly patient
88 ough literature on reduction of LV mass with antihypertensive therapy is extensive, little informatio
89  versus development of new ECG strain during antihypertensive therapy is unclear.
90 re have been advances in management, such as antihypertensive therapy, magnesium sulphate, and fluid
91                                    Different antihypertensive therapies may vary in their effect on L
92 dies have suggested that evening dosing with antihypertensive therapy might have better outcomes than
93 blind candesartan or placebo with open-label antihypertensive therapy (mostly thiazide diuretics) add
94                     Selection of appropriate antihypertensive therapy necessitates the careful consid
95 eeclampsia and to assess the action of other antihypertensive therapies on rcSO2.
96 f incident dementia; however, the effects of antihypertensive therapy on cognitive function in contro
97              The long-term effect of chronic antihypertensive therapy on growth, as well as the preve
98                              Despite current antihypertensive therapies, only a small proportion of p
99 combined outcome of MI and stroke than other antihypertensive therapies (OR, 0.49; 95% CI, 0.32-0.77)
100  diabetes mellitus, systolic blood pressure, antihypertensive therapy, prior coronary disease, and le
101                                          All antihypertensive therapies protected against cardiorenal
102 hest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo a
103                                              Antihypertensive therapy reduces the risk of cardiovascu
104 with hypertension who were not receiving any antihypertensive therapy (relative hazard, 0.91; 95 perc
105  of electrocardiographic LVH criteria during antihypertensive therapy remains unclear.
106 baseline severity of ECG LVH, losartan-based antihypertensive therapy resulted in greater regression
107                            High adherence to antihypertensive therapy results in a significant reduct
108 sis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reduc
109                                              Antihypertensive therapy should be adjusted according to
110            Barbiturates offer an alternative antihypertensive therapy since they decrease blood press
111                  These findings suggest that antihypertensive therapy targeted at regression or preve
112                                              Antihypertensive therapy targeted at regression or preve
113 ave less regression of CP LVH in response to antihypertensive therapy than patients without diabetes,
114                                              Antihypertensive therapy that did not include renin-angi
115                Despite the marked changes in antihypertensive therapy that had occurred, BP remained
116 relative to those who adhered to statins and antihypertensive therapy, the odds ratio at the year of
117 or age, sex, systolic blood pressure, use of antihypertensive therapy, total and high-density lipopro
118 tics will rightfully remain a cornerstone in antihypertensive therapy, we should remember (as we were
119 calation (patients receiving monotherapy) of antihypertensive therapy were included.
120 major changes in the clinical guidelines for antihypertensive therapy were introduced.
121           Renal dysfunction and the need for antihypertensive therapy were much the same in both grou
122 atory data, as well as immunosuppressive and antihypertensive therapy were recorded.
123 males; mean age: 60 22 years; 32% prescribed antihypertensive therapy) were analyzed.
124 derate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting
125 nsion (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine
126 HEP) trial, conducted between 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepp
127              However, participants receiving antihypertensive therapy (with blood pressure controlled
128         Initiating or intensifying statin or antihypertensive therapy within 1 year of enrollment, me
129  partitioning to assess the probability that antihypertensive therapy would be increased at a given c
130       The median (IQR) estimated chance that antihypertensive therapy would prevent a cardiovascular

 
Page Top